Pareeta Kotecha
Real-World Adherence and Outcomes Associated with Glucagon Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Type 2 Diabetes
Abstract
Obesity affects 1 in 5 children and adolescents and is a leading risk factor for type 2 diabetes (T2D), yet treatment options remain limited. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed in this population, but adherence and psychological safety remain unclear. This study will assess individual and pooled risks of psychological outcomes – depression, suicidal ideation/behaviors, anxiety, associated with GLP-1 RA versus metformin use in children and adolescents with obesity or T2D using 2019-2025 OneFlorida+ EHR and MarketScan claims data. GLP-1RA adherence in children and adolescents will be measured via proportion of days covered in MarketScan data. To enhance patient-centeredness, we will further conduct qualitative studies to understand facilitators and barriers associated with GLP-1RA adherence in children and adolescents from the perspectives of patients, parents, and providers.
I am grateful to receive the PhRMA Foundation award. This award provides meaningful support to international students and early-career researchers like me to advance their skills in outcomes research. I hope this research can make meaningful impact and increase surveillance in pediatric populations using GLP-1 RAs.
